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Abstract
Heart failure (HF) and cardiovascular diseases present public health challenges. Although 
great progress was achieved in their treatment, there is continuous need for new therapies. 
Urocortins of the corticotropin neuropeptide family were reported to exert beneficial ef-
fects in animal models of HF and cardiovascular diseases. We aimed to assess the avail-
able clinical evidence on the potential role of urocortins in HF and other cardiovascular 
diseases. We explored MEDLINE, Embase, CENTRAL, and Scopus databases. Twenty- 
seven studies were included in the qualitative and 15 studies (2005 patients) in the quan-
titative syntheses. Available data allowed us to meta- analyze the blood pressure (BP) 
lowering and heart rate (HR) increasing effects of urocortin 2 in HF with reduced ejection 
fraction. We applied meta- regression to explore the association between left ventricular 
ejection fraction and serum urocortin 1 and urocortin 2 levels. Short- term urocortin 2 infu-
sion decreased mean arterial pressure in chronic HF with reduced ejection fraction (mean 
difference = −9.161 mmHg, 95% confidence interval [CI] −12.661 to −5.660 mmHg, 
p < 0.001). Such infusions increased HR mildly (mean difference = 5.629 beats/min, 
95% CI 1.612 to 9.646 beats/min, p = 0.006). Although some studies reported increased 
urocortin 1 and urocortin 2 levels in HF with growing severity, our meta- regressions failed 
to confirm associations between blood urocortin levels and left ventricular ejection frac-
tion. Clinical evidence confirms short- term BP lowering effects of urocortin 2, whereas 
individual studies report additional beneficial effects. Further clinical investigations are 
necessary to confirm the latter and the long- term value of these peptides in cardiovascular 
diseases. Review protocol: CRD42020163203.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Heart failure (HF) is a cardiovascular disease of outstanding importance, in which 
there is an ongoing need to develop new therapies. Based on evidence from animal 
studies and from isolated human coronary arteries, they indicate that urocortins play 
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INTRODUCTION
The prevalence of heart failure (HF) and other cardiovascu-
lar diseases shows an increasing tendency worldwide.1,2 The 
lifetime risk of HF at the age of 40 approaches 20% in the 
general population.3 Despite the progress in the treatment op-
tions, the healthcare burden of HF and other cardiovascular 
diseases is increasing with population aging worldwide.1,2 
According to experts, there is an ongoing need to develop 
new therapies for HF and other cardiovascular diseases.2,4 
The mechanism of action of such new treatments includes 
enhancement of myocardial contractility or lusitropy, reduc-
tion of the vascular resistance, enhancement of angiogenesis 
or cell viability, to name just a few.4
Urocortins (Ucns) are members of the corticotropin neu-
ropeptide family that are also produced along with their 
receptors in peripheral tissues.5,6 Evidence from animal 
studies indicate that Ucns, especially specific agonists of 
corticotropin- releasing factor type 2 receptors (CRF2R), 
such as Ucn2 and Ucn3 play a complex beneficial role 
in cardiovascular disorders.6– 8 These hormones are pro-
duced in peripheral tissues, including blood vessels and 
the heart.9– 11 Moreover, CRF2Rs also show high levels of 
expression in the cardiovascular system.10 Specific ligands 
of CRF2R were demonstrated to induce positive inotropic, 
lusitropic, and vasodilatory effects, among others.6 The fact 
that CRF2R knockout mice develop hypertension suggests a 
role for CRF2R in the regulation of blood pressure (BP).12,13 
Another study demonstrated that specific CRF2R agonist 
Ucn2 decreased BP in hypertensive rats.14
Urocortin 2 also induced vasodilation in isolated human 
coronary arteries.15 Preliminary clinical studies suggest a 
positive therapeutic potential of these hormones in cardio-
vascular diseases, based on increases in cardiac output and 
in left ventricular ejection fraction (LVEF).7,8 Some studies 
demonstrated elevated blood levels of Ucns in cardiovascular 
diseases.8 In order to decide whether Ucns could serve as ther-
apeutic tools or as biomarkers in cardiovascular diseases and 
HF, further investigations are needed.
Our systematic review and meta- analysis aimed to assess 
the available clinical evidence with regard to the potential 
role of Ucns as biomarkers or therapeutic options in HF and 
other cardiovascular diseases. We present our work in accor-
dance with the preferred reporting items for systematic re-
views and meta- analyses (PRISMA) checklist.16
METHODS
Data collection and search strategy
Our systematic review and meta- analysis were conducted 
based on the Cochrane Handbook guidance17 and reported 
using the PRISMA guideline.16 The article was registered 
in PROSPERO on April 28, 2020 (CRD42020163203). 
The systematic search was carried out in four databases: 
MEDLINE, Embase, CENTRAL, and Scopus. The follow-
ing search terms were used on May 4, 2020: (urocortin OR 
ucn) AND (cardi* OR heart* OR “vascular resistance” OR 
vasodil* OR vasoconst*). We did not use any filters. After 
the selection, the articles’ reference lists were manually 
screened for other eligible publications. We also searched 
Google Scholar for articles citing our relevant records.
Selection and eligibility criteria
The selection of the articles was carried out by two inde-
pendent authors (D.K.K. and A.S.). Following screening for 
a beneficial role in cardiovascular disorders. These hormones and their receptors are 
produced in peripheral tissues, including blood vessels and the heart.
WHAT QUESTION DID THIS STUDY ADDRESS?
Our systematic review and meta- analysis aimed to assess the available clinical evi-
dence with regard to the potential role of urocortins as therapeutic options in chronic 
HF with reduced ejection fraction (HFrEF) and other cardiovascular disorders.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Urocortin 2 has a potential to improve cardiovascular functions in HF via vasodilation- 
mediated suppression of the mean arterial pressure (MAP). Side- effects include mild 
increase in heart rate and flushing. Meta- regression did not show any association be-
tween left ventricular ejection fraction and blood levels of urocortin 1 or urocortin 2.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
These findings confirm that urocortin 2 has a potential to decrease MAP in chronic 
HFrEF. Further studies are needed for the better understanding of the long- term car-
diovascular effects and the safety of urocortin 2 infusions.
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duplicates, the main part of the selection involved three stages. 
The first stage was screening by title, in the second stage, pub-
lications were screened for eligibility based on the abstracts, 
and in the third stage, selection was based on full- text evalu-
ation. Disagreements were settled by a third party (author 
M.B.). Only human studies were included into this systematic 
review and meta- analysis. We included studies, which inves-
tigated the cardiovascular effects of Ucn1, 2, or 3, and studies 
which measured the blood Ucn levels in healthy volunteers 
or in patients with cardiovascular diseases. Exclusion criteria 
were: participants below the age of 18 years, pregnancy, in 
vitro experiments, studies with tissue samples, animal stud-
ies, articles without cardiovascular data, reviews, editorials, 
letters, notes, case- reports, and abstracts without proper data.
Data extraction
Two authors (D.K.K. and A.S.) extracted data from the 
articles, including the names of first authors, year of the 
publication, study design, intervention therapy, Ucn doses, 
durations of the interventions, epidemiology of the popula-
tions, investigated diseases, blood Ucn levels, and param-
eters of cardiovascular functions, such as heart rate (HR), 
mean arterial pressure (MAP), systolic and diastolic blood 
pressures (SBP and DBP), cardiac output (CO), systemic 
vascular resistance, etc. A third author (M.B.) resolved any 
disagreement. Data were extracted from figures of articles 
by the application of the WebPlotDigitizer online pro-
gram.18 For meta- regression analysis, we collected every 
study that measured Ucn levels and LVEF, as well. To carry 
out the meta- regression analysis, we had to convert the dif-
ferent values of Ucn1, N- terminal- pro- Ucn2 (NT- ProUcn2) 
and Ucn2 levels to the same units. Thus, we converted pg/
dl, pg/ml, ng/L, ng/ml values to pmol/L units, based on the 
molecular weights of different Ucns.19– 21
Risk of bias and quality assessment
Quality assessment was carried out by two investigators (au-
thors M.B. and D.K.K.). For randomized controlled trials 
(RCTs), the Cochrane Risk of Bias Tool 1,17 for nonrand-
omized studies the nine- star Newcastle- Ottawa Scale adapted 
for cross- sectional and for cohort studies22 were applied. We 
also used the GRADE score to evaluate the certainty of evi-
dence.23,24 All disagreements were solved by consensus.
Statistical analysis
From the individual studies, we collected information about the 
HR and MAP at baseline and after 25 μg Ucn2 administration 
(via short- term infusion). There was one study where the value of 
change (difference between the post- treatment values of the pla-
cebo and those of the Ucn2 groups) was given.25 From the availa-
ble information, we calculated mean differences (MDs) with their 
95% confidence intervals (CIs) between the control and interven-
tion groups. We used random effect models in each of the meta- 
analyses calculating with the DerSimonian and Laird weighting 
method. Results of the meta- analyses were displayed graphi-
cally using Forest plots. Heterogeneity was tested by using the 
Cochrane’s Q and the I2 statistics, where I2 = 100% × (Q−df)/Q, 
and represents the magnitude of the heterogeneity (moderate: 
30%– 60%, substantial: 50%– 90%, and considerable: 75%– 100%). 
We applied this test to assess whether the heterogeneity observed 
among MDs could be attributed to random chance or to other 
factors (e.g., body mass index [BMI], age, and sex of the partici-
pants). We considered the Q test significant if p < 0.1.17 We used 
meta- regression models to explore the association between LVEF 
and serum levels of Ucn1 and Ucn2. In each case, we tested the 
whole model (simultaneously hypothesized that all coefficients 
are zero) and reported the regression coefficients, 95% CIs, stand-
ard errors, and z tests. We also calculated the explained variance 
of the model (R2 analogue) and the result of the Q test to evaluate 
if the unexplained variance was zero. All statistical analyses were 
performed with Comprehensive Meta- Analysis software version 
3 (Biostat Inc.) and Stata version 15.1.
RESULTS
Results of search and selection
Our systematic search identified 4385 articles. The flow dia-
gram describes the process of the search and selection with 
exclusion criteria in Figure 1. At the end of the selection pro-
cess, we found 27 articles for the qualitative assessment and 
15 studies with data of 2005 patients could be included in the 
statistical analyses.
Characteristics of the studies included
With regard to Ucn1, 12 studies measured the plasma lev-
els in healthy volunteers26 and in patient groups with various 
cardiovascular diseases, such as acute myocardial infarction 
(AMI; with or without controls)27 or HF.28– 38 Seven stud-
ies reported significantly increased blood Ucn1 levels in 
cardiovascular diseases as compared with healthy controls 
(Table 1).27,28,32,34,36– 38
Only one research team administered an infusion of this 
hormone to healthy volunteers and to patients with HF.26,30 
The characteristics of these studies are summarized in Table 1.
Blood Ucn2 levels were reported by 10 studies.21,29,31,39– 45 
Five studies showed significantly increased blood Ucn2 
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levels in cardiovascular diseases, such as coronary artery dis-
ease,43 chronic HF,21,44 hypertension,39 and abdominal aortic 
aneurysm41 (Table 2).
Cardiovascular effects of this hormone were tested in healthy 
volunteers,25,40,46,47 in acute decompensated HF29 and in chronic 
HF.25,31,46 Their characteristics are described in Table 2.
Blood Ucn3 levels were not reported in cardiovascular 
patients. The blood level of the peptide of healthy volunteers 
was reported by one study.11 An additional study reported 
Ucn3 levels in normal weight, overweight diabetic, and over-
weight nondiabetic patients.48 Another study reported ele-
vated Ucn3 levels in subjects with newly diagnosed type 2 
diabetes mellitus as compared with controls.49
Two clinical studies administered Ucn3 infusion to 
healthy volunteers25,47 and to patients with HF25 (Table 3).
Hemodynamic effects of urocortin 1 infusion
Short- term Ucn1 infusion did not change any of the hemo-
dynamic parameters (HR, SBP, DBP, and CO) in healthy 
volunteers26 and in patients with stable congestive HF30 
(Table 1).
Hemodynamic effects of urocortin 2 infusion
In healthy volunteers, Ucn2 infusion increased CO, cardiac 
index, and HR and induced a decrease of DBP, MAP, and 
the peripheral vascular resistance (PVR)25,40,46,47 (Table 2).
Short- term Ucn2 infusion decreased MAP in patients with 
stable HF with reduced EF (HFrEF) (MD = −9.161 mmHg, 
95% CI −12.661 to −5.660  mmHg, p  <  0.001; Figure  2). 
Substantial heterogeneity based on I- squared  =  74.377%, 
p  =  0.020 was calculated. Small- study effect could not be 
calculated because of the low number of available studies.
Short- term Ucn2 infusion increased the HR in patients 
with stable HFrEF (MD  =  5.629, 95% CI 1.612 to 9.646, 
p = 0.006; Figure 3). Substantial heterogeneity based on I- 
squared = 72.134%, p = 0.028 was calculated. Small- study 
effect could not be calculated because of the low number of 
studies.
F I G U R E  1  Preferred reporting items 
for systematic reviews and meta- analyses 
(PRISMA) Flow diagram of the search 
and selection process. Two independent 
reviewers searched and reviewed papers and 
extracted data. Disagreements were settled 
by a third party
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In acute decompensated HF (LVEF% <40%), Ucn2 infu-
sion decreased SBP, DBP, and calculated total peripheral re-
sistance without increasing the HR significantly29 (Table 2).
Hemodynamic effects of urocortin 3 infusion
Ucn3 infusion has been shown to increase the cardiac index 
and the HR, and to decrease the MAP and the PVR index in 
patients with HF and healthy controls alike, although it failed 
to change stroke volume.25 Other researchers reported that 
the infusion of the peptide decreased the DBP (but not the 
SBP) and increased the HR in healthy volunteers.47
Association between left ventricular ejection 
fraction and blood levels of urocortins
Meta- regressions did not show significant associations be-
tween the LVEF of healthy volunteers and patients with 
various cardiovascular diseases and their blood Ucn1 level 
(number of groups: 14, coefficient: 0.026, p = 0.740, r- square 
analogue: 0.00%) or blood Ucn2 level (number of groups: 12, 
coefficient: 0.173, p = 0.465, r- square analogue: −11.22%; 
Figures  S1 and S2). The goodness of fit of the regression 
lines are poor in both cases. The heterogeneity of the data 
may stem from the varied methodology of the measurements 
of blood Ucn1 and Ucn2 levels and from the different patient 
populations (with hypertension, AMI, aneurysm of the ab-
dominal aorta, chronic HF, etc.).
Risk of bias assessment and quality of evidence
Our analysis revealed various sources of risk of bias in the 
included six randomized and 21 nonrandomized studies. The 
results of the risk of bias assessments are shown in Table S1 
in the Supplementary information online. Even randomized 
studies failed to report their randomization protocol in some 
cases. We also found some potential bias based on the lack 
of blinding of participants and/or of researchers. Allocation 
concealment was broken in one of the randomized studies, 
in which accidentally biologically inactive Ucn2 was admin-
istered and thus the infusion needed to be repeated with the 
appropriate product.46 Some bias was assumed in association 
with incomplete outcome data, selective reporting, or the 
small number of participants indicated within the category of 
“other bias.” The 21 nonrandomized studies were evaluated 
by the modified or original Newcastle- Ottawa Scale. They 
received four to eight points. The risk of bias of these studies 
showed an even distribution ranging from high to low.
The overall evidence level of the analyzed data, based on 
our GRADE score, was very low for all four outcomes. We 
included mostly nonrandomized interventional and observa-
tional studies. All of our analyses showed substantial heteroge-
neity. Study populations of the meta- regressions varied from 
healthy volunteers to groups of patients with acute or chronic 
HF, hypertension, aortic aneurysm, metabolic syndrome, and 
diabetes mellitus. Results also showed wide CIs. Therefore, 
we needed to downgrade the level of our evidence (Table S2).
DISCUSSION
In our systematic review and meta- analysis, we assessed the 
available clinical evidence with regard to the potential thera-
peutic role of Ucns in various cardiovascular diseases and the 
association between their plasma level and LVEF.
A large body of evidence from animal studies indicated 
that Ucns, especially agonists of CRF2R, play a predom-
inantly beneficial role in cardiovascular disorders. These 
hormones are produced in a wide variety of peripheral tis-
sues, including blood vessels and the heart.6– 8 High levels of 
expression of CRF2R were also detected in these peripheral 
tissues. Activation of CRF2R was shown to affect myocardial 
and vascular functions, including vasodilatory, positive ino-
tropic, and lusitropic effects. BP of CRF2R knockout mice 
was found to be higher, suggesting a potential role of these 
receptors in the regulation of BP.13 Another research group 
found that Ucn2, a specific CRF2R agonist, decreased BP 
without increasing the HR in hypertensive rats.14 Previous re-
views unequivocally suggested positive therapeutic potential 
of these hormones in cardiovascular diseases.6– 8 They em-
phasized the need for appropriate clinical studies, and they 
saw great potential in manipulating the bioactivity and/or sig-
nal transduction of Ucns for therapeutic purposes.
Concerning the therapeutic potential of Ucns, we searched 
for studies that tested the effects of these hormones in cardio-
vascular diseases.
With regard to Ucn2, the available clinical data allowed 
us to perform meta- analyses on the effects of short- term in-
fusions (at a dose around 25 μg) only in patients with chronic 
HFrEF. These infusions significantly decreased MAP and 
mildly increased HR compared to placebo. It appears that 
the decrease in MAP was a result of a reduction of periph-
eral vascular resistance. Within 40– 60  min following the 
infusions, all cardiovascular parameters returned to baseline 
values. The BP lowering effects of Ucn2 may be beneficial 
for patients with HF, because it indicates a decrease of the 
afterload.50 The Ucn2 infusion- induced rise in HR would, 
on the other hand, increase the oxygen consumption of the 
myocardium and reduce the diastolic time. Clinical studies 
and patient registry analysis demonstrated that lower HR or 
additional reduction of HR improved the mortality rates in 
HF.51,52 In our analysis, the rise in HR due to the Ucn2 infu-
sion was fortunately minimal.
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Although individual studies reported decreases of SBP 
and DBP29,31,47 or total peripheral resistance,25,29,31,40,46 an 
increase in CO, cardiac index,25,29,31,40,46 or forearm blood 
flow,47 we could not meta- analyze these important cardiovas-
cular parameters because of the lack of appropriate amount 
of data (Table 2). Urocortin 2 infusions did not induce rises 
in blood cortisol, plasma creatinine, N- terminal- pro brain 
natriuretic peptide, plasma renin, angiotensin II, and aldoste-
rone.29,31,40 Thus, these infusions did not induce activation 
of the hypothalamo- pituitary- adrenal cortical (HPA) axis, or 
a reduction of renal blood flow, or an abnormal stretch of 
the ventricles, or other cardiovascular adaptive responses that 
would indicate hypotension of a dangerous extent.
Because of the lack of a sufficient number of available 
studies, we could not meta- analyze the data on the effects 
of Ucn1 or Ucn3 in HFrEF (Tables 1 and 3). The available 
studies have shown that Ucn1 infusion failed to change car-
diovascular parameters, but it increased the activity of the 
HPA axis, as shown by the increase in blood cortisol.26,30 
Concerning Ucn3, the infusion of this hormone has been re-
ported to elicit strong vasodilatory effects in patients with 
HFrEF but not in healthy volunteers.25
With regard to side effects, no adverse events were de-
tected during Ucn1 infusions either in healthy volunteers or 
in patients with HF.26,30 On the other hand, the Ucn2 and 
Ucn3 infusions induced a number of adverse symptoms. 
Flushing due to vasodilation developed in the majority of the 
participants.25,29,31,40,46,47 In some cases, the infusion had to 
be stopped due to hypotension or syncope.25 Some patients 
complained about increased HR sensation.40,47 Rarely, as-
ymptomatic nonsustained ventricular tachycardia devel-
oped.29 In acute decompensated HF, Ucn2 infusion- induced 
hypotension was associated with transiently reduced urine 
volume and creatinine clearance.29
Sporadic, rare adverse events detected on the day of the 
Ucn2 or Ucn3 infusions also included mild and transient 
hypokalemia with postprandial hyperinsulinemia, dizzi-
ness, hyponatremia, headache, anorexia, or hyperamylase-
mia.25,29,31,40,46,47 Thus, contraindications to Ucn2 infusions 
would include hypotensive states, tachycardias, or renal 
failure.
With regard to the blood levels of Ucns in cardiovas-
cular diseases, we found numerous clinical studies that 
confirmed increased blood levels of Ucn1 and Ucn2 in a 
wide variety of cardiovascular diseases from hyperten-
sion to chronic HF, or from atrial fibrillation to aortic 
aneurysm21,27,28,32,34,36– 39,41,43,44 (Tables 1 and 2).
Concerning Ucn1, most studies confirmed higher hor-
mone levels in HF or AMI27,28,32,34,36– 38 as compared with 
controls. However, Ucn1 levels did not always correlate 
with the severity of the disease.33,34 Our meta- regression 
also failed to confirm any correlation between serum 
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studies demonstrated correlations between Ucn1 levels 
and the New York Heart Association (NYHA) stage of the 
HF.36– 38
Urocortin 2 levels were also higher in chronic HF,44 in hy-
pertension,39 in coronary artery disease,43 or in patients with 
aneurysm of the abdominal aorta.41 One study found higher 
NT- ProUcn2 level in patients with HF with more severe dis-
ease.21 However, certain studies found a lack of association 
between Ucn2 and LVEF.29,43 It is interesting that treatment 
modalities in hypertension also appeared to influence Ucn2 
levels. Walczewska and coworkers found higher Ucn2 levels 
in angiotensin convertase enzyme inhibitor- treated patients 
as compared with the angiotensin receptor blocker- treated 
group.45 In addition, adrenergic alpha- blockers seemed to de-
crease Ucn2 levels.45
With regard to Ucn2, once again, meta- regression 
failed to confirm the hypothesized correlation between in-
creasing blood Ucn2 levels and decreasing LVEF values 
(Figure S2).
In case of Ucn3, higher hormone levels were demon-
strated for a number of pathological conditions, such as met-
abolic syndrome, diabetes mellitus type 2, polycystic ovary 
syndrome (PCOS), or obesity, but not for HF or for other car-
diovascular diseases.48,49,53
Because all Ucn levels were determined by ELISA tech-
niques, gross differences in measurement could not contribute 
F I G U R E  2  Hemodynamic effects of urocortin 2 infusion: change in mean arterial pressure (MAP) [mmHg] following urocortin 2 (Ucn2) 
versus placebo infusion. Squares show the mean difference (MD) of mean arterial pressure (MAP) [mmHg] after urocortin 2 (Ucn2) infusion versus 
placebo infusion. The black center area reflects the weight assigned to the study. Horizontal bars indicate 95% confidence intervals (95% CIs). The 
diamond shows the overall MD with its corresponding 95% CI
F I G U R E  3  Hemodynamic effects of urocortin 2 infusion: change in heart rate (HR) [beats/min] following urocortin 2 (Ucn2) versus placebo 
infusion. Squares show the mean difference (MD) of heart rate (HR) [beats/min] after urocortin 2 (Ucn2) infusion versus placebo infusion. The 
black center area reflects the weight assigned to the study. Horizontal bars indicate 95% confidence intervals (95% CIs). The diamond shows the 
overall MD with its corresponding 95% CI
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to the substantial heterogeneity of our results. Other factors, 
such as BMI, age, and sex, may have contributed to the het-
erogeneity of these findings.21,39,42,43
Interestingly, we did not find remarkable differences among 
Ucn types and in their association with specific cardiovascular 
diseases. Moreover, blood Ucn levels appear to increase in a 
number of other general systemic challenges, including meta-
bolic syndrome,49 PCOS,53,54 or type 2 diabetes mellitus.48,49 
Thus, increases in Ucn levels may not even be specific for car-
diovascular disorders or HF.
In the future, regression analyses will be worthwhile if 
enough data pairs from large patient registries for cardiovas-
cular parameters in well- defined cardiovascular disorders 
will become available.
Various limitations have to be considered with regard to 
the present systematic review. Due to the lack of classical 
RCTs, we had to analyze observational, nonrandomized inter-
ventional studies or randomized crossover studies. Moreover, 
the small study populations also limit the generalizability of 
our results. With regard to Ucn2 infusions, the dose of 100 μg 
was the most effective in increasing the CO and in decreas-
ing the total peripheral resistance in healthy volunteers and 
cardiac patients.31,40 Unfortunately, there was no sufficient 
clinical data with this dose for proper meta- analysis. Thus, we 
had to analyze data with the dose of 25 μg. Some results had 
to be extracted from graphs. The risk of bias of the individual 
studies ranged from moderate to low, however, the certainty of 
evidence according to GRADE was very low for all outcomes.
The usefulness of vasodilatory agents in HF have also 
been questioned by recent clinical trials.55 For example, va-
sodilatory agent serelaxin, and the decreased BP failed to 
improve the 180- day mortality in acute HF in a recent large 
multicentric RCT.55
In order to decide whether Ucns could serve as biomarkers 
to cardiovascular diseases, measurement of Ucn levels would 
have to be included in prospective, large patient registries. 
With regard to the therapeutic use of Ucn2 in HF and other 
cardiovascular diseases, RCTs also measuring changes in 
cardiovascular mortality or in parameters (e.g., NT- ProBNP, 
LVEF, and CO) could provide decisive evidence. Future 
studies could investigate the potential contribution of Ucn2 
to the treatment of hypertension of patients with HF or to 
the acute intervention of hypertensive crises in such patients.
CONCLUSION
Results of our meta- analysis and systematic review confirm 
the suggestions of animal studies and in vitro tests, accord-
ing to which Ucn2 has a potential to improve cardiovascular 
functions in HF. Further clinical studies are needed for the 
better understanding of the long- term cardiovascular effects 
and the safety of Ucn2 infusions. With regard to blood Ucn 
levels as potential biomarkers of cardiovascular diseases, 
we did not find any association between LVEF and Ucn1 or 
Ucn2 levels. Large prospective cardiovascular patient regis-
tries also measuring Ucn levels in acute and chronic cardio-
vascular conditions could help us understand the cause of the 
elevated Ucn levels and their prospective value.
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